Search results

Filter (6 in use)

Area of interest

  • Filter by COVID-19 (2)

Type 4 selected

  • Remove filter for NICE advice (2)
  • Remove filter for indicators
  • Remove filter for local practice
  • Remove filter for research recommendations

Last updated 1 selected

  • Remove filter for Last 3 months
  • Filter by Last 6 months
  • Filter by Last year
  • Filter by Last 3 years

Advice programme 1 selected

  • Filter by Medtech innovation briefings (15)
  • Filter by Evidence summaries (5)
  • Filter by Antimicrobial prescribing (3)
  • Remove filter for COVID-19 rapid summaries (2)

2 results

Sorted by Date . | Sort by Relevance

  • NICE advice Remove NICE advice filter
  • indicators Remove indicators filter
  • local practice Remove local practice filter
  • research recommendations Remove research recommendations filter
  • Last 3 months Remove Last 3 months filter
  • COVID-19 rapid summaries Remove COVID-19 rapid summaries filter
  1. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    ES34 Product overview The content of this evidence summary was up to date in January 2021. See summaries of product characteristics

    Type
    Evidence summary: COVID-19 rapid summary
    Published
    20 January 2021
  2. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    ES33 Product overview The content of this evidence summary was up to date in January 2021. See summaries of product characteristics

    Type
    Evidence summary: COVID-19 rapid summary
    Published
    15 January 2021